A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
ELSA 2004-001
NCT00090090
April 2004
October 2006
Name | Location |
---|---|
Tower Hematology Oncology Medical Group | Los Angeles, California 90048 |
USC Norris Cancer Center | Los Angeles, California 90033 |
Providence Saint Joseph Medical Center | Burbank, California 91505-4866 |
Alta Bates Cancer Center | Berkeley, California 94704 |
North Valley Hematology Oncology Medical Group | Mission Hills, California 91343 |
Cancer and Blood Institute Medical Group | Rancho Mirage, California 92270 |
North Shores University Hospital | Manhasset, New York 11021 |